Study S000603

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obstructive Sleep Apnea and Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06649045
Acronym: ATTAIN-OSA
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 712
Start: 2024-10-22
Primary completion: 2026-07-21
Lead sponsor: Eli Lilly and Company
Conditions: OSA; Overweight or Obesity
Interventions: DRUG:Orforglipron; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:J5P-MC-GZRA; OTHER:J5P-MC-GZ01; OTHER:J5P-MC-GZ02

Registered primary outcomes

Change from Baseline in Apnea-Hypopnea Index (AHI) [Baseline to Week 52]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0002687	Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial. Malhotra A, Contemporary clinical trials communications	2026	Protocol	PMID 42383207 DOI	cites ClinicalTrials.gov:NCT06649045; registry reference DERIVED:42383207